Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like another buying opportunity this morning - and maybe for some time yet.
Well that sucks!
Wonder if Pauline will post earnings today?
Was there a reason given for the downgrade?
Epigenetic testing; yes, to answer your question. In the Pacbio website under the Applications tag is a tag for epigenetics where you can learn more.
So now the testing requires not only that we know a DNA sequence, but we are going to need to know what epigenetic switches are turned on (or not).
Epigenetic marks. Fascinating you should mention that as I have been reading up on that aspect of our DNA. Pretty fascinating stuff really; one book says these marks can be created by, "infections, injuries and infatuations". Infatuations! You mean an old girlfriend from my college days can influence my DNA! oh Wow.
I believe I remember from the web site that they do some epigentic reads. The DNA story just gets more fascinating all the time!
I'll hunker with you Shrub.
I'm surprised ILMN hasn't gone after them already - but maybe IlMN already has their hands full. At some point in the earnings CC someone (don't remember who it was) said in response to a question that in many? some? ways the two are complementary. I took that to mean not so much competitive as complementary.
So here too is why the longer reads look to make sense to me;
"so
the partners teamed up to better
understand the genes associated with
this resistance. They tried short-read
sequencing, but after eight library
preparations and investing over a
year on the project, they were still
missing 16 percent of the genome,
and the assembly contained highly
fragmented genes. Deeper sequence
analysis suggested the assembly,
in addition to containing gaps, had
problems with repeat regions and
large structural variations."
So the researchers switched to the Pac Bio machines;
"They had
worked on the short-read assembly
for a year, but it took just a couple
of library preparations and a single
month to get data far superior to
the original assembly. Additionally,
complex regions such as repeats and
structural variants were represented
cleanly in the PacBio assembly,
avoiding problems seen in the shortread
assembly."
I still have a hard time understanding why a read out from a genome wouldn't be hugely more beneficial the more accurate it is - without missing sections and gaps. The human genome is one thing - but another is all the other organisms out there that may hold potential. Diseases for instance;
"As plant and animal scientists know all too well, the
lack of a high-quality reference can substantially hinder
biological research. Prior to SMRT Sequencing, options
for decoding plant and animal genomes were suboptimal.
Using short-read sequencing technologies on large,
complex genomes produced highly fractured assemblies,
often with large errors."
Shrub, thanks for your comments.
Not sure if this most recent post was targeted at me and my bullishness for PACB. I surely did not mean to indicate that PACB was going "dominate" the sequencing field. That said, sure does look like they are moving in a positive direction given their expertise in the field.
Seems a bit of a contradiction to me; bully companies to reduce the cost of drugs - then bully them to make more of the drugs here which will likely make them more expensive.
Sounds like a commercial for ILMN. Did you listen to the presentation by PACB? The issue of missed sections of reads - and/or gaps was said said over and over again. That PACB had a real advantage because of this issue. Hype? I suppose some hype sure, but seems like real world advantage by the PACB machines.
Doesn't seem like it should be just a "niche market" to me. As they dig deeper into the genome (human and other organisms) the importance of a correct read will be ever more important.
Some companies are now looking at areas of the genome previously thought of as junk DNA. Not junk at all they are finding out. As they wander out into these obscure DNA areas - won't a longer read become just that much more important? Having missing sections or gaps is like having a manual for an important instrument with pages missing.
Some of the recent post of yours are fascinating. What confuses me a bit is why - given the longer reads by PacBio - they seem unable to compete with ILMN? Aren't we learning more all the time that small differences in a genome are key to disease - or the bodies battle against disease? .......So a complete run of a persons genetic makeup for a $1,000 bucks may provide information about a gene mutation - but may miss the subtleties that would provide information to help diagnose some of the mysteries of cancer - the differences where one person is helped by a drug while another is not?
Surf;
Lessons from Sonus;
<<<When I wrote about Sonus in August, there were several factors that made this seem too good to be true. 1) There were few shorts, 2) All the analysts were talking good about it, and 3) The message boards were too positive>>>
Message boards are likely better counter indicators. The people who want to sell will talk up a stock - that should be a given. I believe there is only one way to determine if insiders are selling or buying and that is with technicals. P&F said to sell in August. As soon as SNUS traded below the blue line in the following chart, it sent out a sell signal and at that price (4.50), it would have saved a lot of money for owners of these shares.
http://stockcharts.com/def/servlet/SC.pnf?chart=snus,PLTADANRBO[PA][D][F1!3!!!2!20]&pref=G
Good Investing
Surf;
You missread my post - I said that P&F gave out a sell signal at 8.50 for INHX. You brought this stock up, I didn't.
If you believe in ....."I look for trend changes over weeks to months"....... as you say, then P&F is prefect for you. The point I was trying to make is that while you said that PANC was sending out one of the "strongest" buy signals ever, that P&F was sending out just the exact signal - to sell. Obviously P&F was the correct signal.
This is very valuable for invstors here at IHUB as it is an easy charting method that anyone can understand.
Respectfully;
natvik
Surf:
I have to answer your INHX comment here as my cheap subscription wouldn't let me respond to your private email - sorry.
INHX most certainly did send out a sell before the stock crashed under P&F. It clearly sent out that signal at 8.5. The nice thing about P&F is that you can easily go back and check - unlike other charting methods.
http://stockcharts.com/def/servlet/SC.pnf?chart=inhx,PLTADANRBO[PA][D][F1!3!!!2!20]&pref=G
natvik
<<Charts can't predict a CEO leaving the company or the reason that he left!>>
I disagree. You must assume that charts have a life of their own, while I believe charts are simply a reflection of real world. They predict when an event such as a winning drug will come out or bad news such as a management change. Do you think that charts can be over studied? I do. The chart I look at clearly said "sell" on PANC. (P&F)
Good Investing!
steve
Surf:
<<PANC is another stock to be buying at current levels, a couple of days ago it had what I consider one of the most bullish chart signals that can be flashed {Strong Volume Gainers (PANC)}>>
What happen here? Charts are suppose to predict.
natvik
Raggs;
Coming back from Monterey last weekend, we caught the train in Salinas. Many of the newspapers we saw were in spanish, but the one word in the very large headline, "E.coli", was blaring. Salinas was were the E'coli tainted spinach was recently traced to. Very big news to the workers it looked like.
Still though I like the antibody business better than their testing stuff.
Raggs;
Coming back from Monterey last weekend, we caught the train in Salinas. Many of the newspapers we saw were in spanish, but the one word in the very large headline, "E.coli", was blaring. Salinas was were the E'coli tainted spinach was recently traced to. Very big news to the workers it looked like.
Still though I like the antibody business better than their testing stuff.
Yes, I do a lot of short term trading, but I have had SDIX for years and expect to hold for much longer. They have a tremendous amount of science and going into ever more interesting business segments. Technicals look terrific too - stars se4em to be lining up.
Vicente Anido the former CEO of CRXX is now at ISTA. ISTA is hitting on all cylinders and seems to have no interest by retail investors. Any comments on ISTA or Anido will be appreciated!
Zebra's law huh. Too bad if that is the case. Throw out ANA380 - what value does that give ANDS? Do you - or does anyone - have any feel for their antibacterial program?
DEW;
If you are correct about ANA380 why wouldn't ANDS just take the hit on it now? Get it over with? That seems to make more sense than a constant bleed .........and then a hit? Jeepers enterprise value is getting close to nothing?
steve
raggs; News today pushed SDIX into a bullish P&F chart pattern. First time since 04, so might be a turning point. Doesn't matter to me which way it goes as I will buy more if it goes down.
Nice couple of news releases and I suspect more to come!
natvik
Surf;
You like these beat up too cheap to believe biotechs don't you? It may be a worthwhile strategy as long as a person has the patients to stay with them...... Do you have a reason for buying ONCY - other than that it's price has been beat down?
steve
Oh ya, likely way too many! Including this one.
steve
Great question;
My guess is either anticapation of news coming out of their presentation - or mischief. There has been some mischief with thinly traded stocks - including I gather some biotechs - where offshore accounts push up a stock and the sell into the strength. They apparently can push up a stock by hacking into some of our accounts and using our money to buy.
Good question though as the volume was NOT insignificant.
Good Investing;
steve
Worm DR;
Care to editorialize on your thinking here? Okay, lot of short interest, but who would ever short a 3 dollar biotech at this price? Are you thinking this is a bottum?
steve
See if I have this right;
Someone breaks into your account and then they are able to pump up a stock by using your funds to buy the equity - in this case DYAX. Since they know there is going to be a large increase volume - because they are doing it - they are able to buy ahead of time and then cash out when the stock goes up!
This is too weird as the pumpers will still win and the ones penalized are the individual investor. Might be that they won't win as much - but that seems rather wrong-headed thinking to me. Don't they need to stop it all together? Not the brokers fault, but rather a completely feckless SEC which just won't go after the bad guys!
steve
Sure, wait until they have to disclose it. If you are a heavy player and want to buy, why wait for a light volume day though? Makes little sense. I think it is more likely that it was indeed a pump and dump scheme by -buy- someone.
The better question to ask though - (I think I will as soon as I get done writing this response) - is to ask ScotTrade (or Ameritrade) what triggered their STOP on internet orders. When I tried to trade early on the volume was in the 100's of thousands rather than millions. I will now wait until the company has a chance to respond.
steve
genisi;
According to ScotTrade there is something mischievious going on. I originally thought it was someone trying to establish a position - the reason I wanted to buy. I now think that perhaps scotTrade is right! 2.6 million shares is not someone opening a position!! There is no way DYAX can come out with any news in the near future, as it would imply (er, mean) that information leaked.
Someone suggested that if they wanted to buy that they should be allowed to - well there is nothing stopping a person from calling their broker and placing the trade. Frankly I applaud the retail brokers on trying to get a handle on this, but question if these tatics by the brokers will work.
steve
Dew;
"kludgy"? Interesting choice of words - even as I agree.
More importantly - especially given the swings - and volume - of DYAX is trying to figure out what the heck happened. Frankly, scotTrade saved me some money this morning. It is hard to tell if these are pump and dump or legitimate efforts by someone to enter a security.
Thanks for the comments;
steve
How do you know they got "so little out of it"? They might be working on something great? Or the program might be dead?
As to DYAX, see my comments on the Biotech valuation page re: ScotTrade comments to me this morning.
steve
Re: DYAX;
What about their libraries program? Seems to be some real value there - but it also looks like they gave up some of the near term earnings from it.
A personal note on DYAX: I tried to place an order through ScotTrade on this stock this morning and was unable to do so online. When I called, ScotTrade said some of these companies are the target of pump and dump schemes - maybe the volume today triggered that with DYAX? I was surprised as it is the first time I have been unable to place an order!
Steve
One would hope that within the last two years they would have gotten something out of the DYAX "co-development and target inlicensing"? Since it looks to me that Dyax gave up much of the near term income from their libraries program, it might mean they will devote more efforts toward their co-development agreements that were already in place?
steve
surf;
Not sure how much research you have given this stock - do you have any understanding of the agreement that IHNX has with DYAX? Appreciate your comments!
steve
Some news - more to come maybe?
http://biz.yahoo.com/prnews/061120/clm087.html?.v=6
steve
Surf:
I would not disagree. My gosh, this puppy has a negative enterprise value of like 5 million or so. Seems like the sellers are likely out of the stock by now and when it goes, there may not be a lot of sellers left?
You didn't call and talk with management did you?
Good Investing;
steve